

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Geoffrey Brooke
Date of last notice	1 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary 3. Dalhigh Pty Ltd <Dalhigh Investments A/C> - director and beneficiary
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	1. 300,000 unlisted options exercisable at \$2.11, exp 16/11/2024. 2,000,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions. 2. 117,809 ordinary shares 3. Nil
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	3. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$29,999.81
No. of securities held after change	<ol style="list-style-type: none"> 1. 300,000 unlisted options exercisable at \$2.11, exp 16/11/2024. 2,000,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions. 2. 117,809 ordinary shares 3. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Ross Macdonald
Date of last notice	30 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Held in the name of wife – Mrs Sharon Anne Macdonald
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	1. 2,000,000 ordinary shares 1,500,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions 2. 70,050 ordinary shares
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	2. 55,813 ordinary shares 27,907 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$11,999.80

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 2,000,000 ordinary shares 1,500,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions 2. 125,863 ordinary shares 27,907 listed options exercisable at \$0.30 exp 1/4/2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Darryl Maher
Date of last notice	30 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions.
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	50,000 ordinary shares 25,000 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$10,750

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	50,000 ordinary shares 25,000 listed options exercisable at \$0.30 exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Janine Rolfe
Date of last notice	23 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Rolfe Pty Ltd <J&R Rolfe Superannuation Fund> - director of trustee and beneficiary of fund
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	1. 300,000 unlisted options exercisable at \$0.51, exp 23/11/2027 and subject to vesting conditions.
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	2. 116,279 ordinary shares 58,140 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$24,999.99

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 300,000 unlisted options exercisable at \$0.51, exp 23/11/2027 and subject to vesting conditions. 2. 116,279 ordinary shares 58,140 listed options exercisable at \$0.30 exp 1/4/2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Stewart Washer
Date of last notice	2 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> Mal Washer Nominees Pty Ltd <Mal Washer Family Trust> Stewart Washer & Patrizia Washer <The Washer Family S/Fund A/C>
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	<ol style="list-style-type: none"> 2,080,000 ordinary shares 204,856 ordinary shares 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	<ol style="list-style-type: none"> 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$29,999.81

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 2,219,534 ordinary shares 69,797 listed options exercisable at \$0.30 exp 1/4/2025 2. 204,856 ordinary shares 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Paul K Wotton
Date of last notice	30 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Citicorp Nominees Pty Limited (beneficial interest)
Date of change	31 May 2023 & 1 June 2023
No. of securities held prior to change	1. 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions 2. 175,775 ordinary shares
Class	Ordinary shares Listed Options exercisable at \$0.30 exp 1/4/2025
Number acquired	1. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$29,999.81

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 and subject to vesting conditions 2. 175,775 ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement ordinary shares and listed options as approved at Extraordinary General Meeting held 25 May 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.